Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 B cell immunology for the clinician.

Literature DB >> 21242750

B cell immunology for the clinician.

Carolina Marcus¹, Gitika Dhillon, Jennifer H Anolik.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Year: 2011 PMID： 21242750 PMCID： PMC3561734 DOI： 10.1097/INF.0b013e318207447f

Source DB: PubMed Journal: Pediatr Infect Dis J ISSN： 0891-3668 Impact factor: 2.129

× No keyword cloud information.

27 in total

Review 1. B cells as therapeutic targets in SLE.

Authors: Iñaki Sanz; F Eun-Hyung Lee
Journal: Nat Rev Rheumatol Date: 2010-06 Impact factor: 20.543

2. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

Authors: P P Sfikakis; J N Boletis; S Lionaki; V Vigklis; K G Fragiadaki; A Iniotaki; H M Moutsopoulos
Journal: Arthritis Rheum Date: 2005-02

3. Practice parameter for the diagnosis and management of primary immunodeficiency.

Authors: Francisco A Bonilla; I Leonard Bernstein; David A Khan; Zuhair K Ballas; Javier Chinen; Michael M Frank; Lisa J Kobrynski; Arnold I Levinson; Bruce Mazer; Robert P Nelson; Jordan S Orange; John M Routes; William T Shearer; Ricardo U Sorensen
Journal: Ann Allergy Asthma Immunol Date: 2005-05 Impact factor: 6.347

4. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny.

Authors: Jennifer H Anolik; Jonathan W Friedberg; Bo Zheng; Jennifer Barnard; Teresa Owen; Emily Cushing; Jennifer Kelly; Eric C B Milner; Richard I Fisher; Iñaki Sanz
Journal: Clin Immunol Date: 2006-09-27 Impact factor: 3.969

Review 5. 1. Lymphocytes.

Authors: David F Larosa; Jordan S Orange
Journal: J Allergy Clin Immunol Date: 2008-02 Impact factor: 10.793

B cell immunology for the clinician.

Review 1. B cells as therapeutic targets in SLE.

2. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

3. Practice parameter for the diagnosis and management of primary immunodeficiency.

4. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny.

Review 5. 1. Lymphocytes.

Review 6. Self-tolerance checkpoints in B lymphocyte development.

7. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus.

Review 8. B cell depletion therapy in autoimmune diseases.

Review 9. B-cell depletion and repopulation in autoimmune diseases.

Review 10. B cell biology and dysfunction in SLE.

1. Advances in human B cell phenotypic profiling.